Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news claude_news wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi market on whether wild poliovirus 1 (WPV1) cases will hit zero in any year from 2024-2029. Need current market price as anchor, recent WPV1 case counts from Pakistan/Afghanistan (only endemic countries), and GPEI progress reports.

# Event Will there be any calendar year 2024–2029 with zero reported wild poliovirus type 1 (WPV1) cases globally? # Outcomes to forecast - **Yes**: At least one year in 2024–2029 has zero WPV1 cases - **No**: Every year through 2029 has at least one WPV1 case # Kalshi market anchor **Current YES price: 10.30%** (as of latest data) - 7-day change: +2.90% | 30-day change: +3.30% (recent modest upward drift) - Price range over ~119 days: 3.00%–12.00% - Volume: ~245 contracts/day (moderate liquidity) - *Interpretation*: Market consensus strongly favors "No" (~90%), with slight recent movement toward "Yes" # Sub-question answers 1. **Kalshi price for KXPOLIOELIM-30** — 10.30% YES, up ~3pp over 30 days. [kalshi_direct] 2. **WPV1 cases in 2024 and 2025** — 2024: 99 total cases (Pakistan ~74, Afghanistan ~25), a ~8x surge vs. 2023's 12 cases. 2025: 31 cases total (year-end); 2026 as of mid-June: 3 cases. [WHO IHR EC statements, GPEI, CDC] 3. **Case trend in Pakistan/Afghanistan** — Declining from 2024 peak: 443 WPV1-positive environmental samples in 2025 vs. 741 in 2024. However, virus persists in core reservoirs (Karachi, Peshawar, Quetta Block, Southern Afghanistan) and was detected in Germany (environmental, Oct 2025) linked to Kandahar. [WHO 44th IHR EC, Health Policy Watch] 4. **WHO/GPEI on 2027–2029 interruption prospects** — GPEI extended strategy to end-2029; revised target is interrupting WPV1 transmission by end-2025 (already missed) → now targeting certification by end-2027. Multiple deadlines already missed (original target: end-2023). [GPEI strategy extension, WHO IHR EC Dec 2024] 5. **Outbreaks/surges making zero-year less likely** — Yes: 2024 Pakistan resurgence (12x increase) driven by insecurity, 420,000+ unvaccinated children, 200+ campaign boycotts in KPK, cross-border mobility. Environmental spread beyond clinical cases indicates silent transmission. Chaman border hotspot. [ScienceDirect, PMC] # Key facts (high-confidence, factual) 1. [GPEI/CDC] Only Afghanistan and Pakistan remain WPV1-endemic; they form a single epidemiological block. 2. [WHO] 2024 saw 99 WPV1 cases—the highest in years; 2025 dropped to 31; 2026 shows 3 cases as of mid-year. 3. [GPEI strategy extension] Official eradication timeline extended to 2029; transmission interruption target now missed for end-2025. 4. [Wikipedia] WPV2 eradicated 2015, WPV3 eradicated 2019; WPV1 is the sole remaining wild strain. 5. [WHO 43rd IHR EC] 443 WPV1-positive environmental samples in 2025 indicate virus still circulating widely despite fewer paralytic cases. 6. [PMC] Structural barriers: violence, insecurity, vaccine refusal, population mobility remain entrenched. # Cross-market signals - **Kalshi related**: Only one market found (same ticker); no other polio markets exist. - **Polymarket**: No active polio markets found. - **Sportsbook**: N/A. # Analyst opinions and speculation - GPEI's own optimistic scenario (transmission interrupted by end-2026, certified 2027) would allow a zero-case year in 2027, 2028, or 2029—but requires interrupting within ~18 months of current ongoing transmission. [WHO] - Research notes progress is "fragile" and the 2024 rebound from near-elimination shows how quickly gains reverse. [ScienceDirect, PMC] - For resolution Yes, WPV1 must be interrupted by end-2028 at the latest (to yield a full zero-case year before 2030 closes Jan 1, 2030). # Directional lean per outcome - **Yes (10%)**: *Supporting*: 2025–2026 case counts declining sharply; GPEI's best-case scenario still puts interruption within window; 2026 pace (~3 cases mid-year) is encouraging. *Opposing*: Environmental surveillance shows broad silent transmission; all past GPEI deadlines missed; structural barriers (insecurity, refusal) unresolved; only ~3.5 years remain. - **No (90%)**: *Supporting*: Ongoing transmission in 2025–2026 confirmed; GPEI's own target already slipped; history of repeated deadline failures; virus circulating in multiple geographic clusters simultaneously. *Opposing*: Trend is downward; not impossible if 2026–2027 campaigns succeed. # Gaps / unknowns - Whether 2026 political/security situation in Pakistan/Afghanistan improves sufficiently for campaign access. - Whether the ~3 cases reported mid-2026 represent the full 2026 total (seasonality means more cases typically appear mid-year). - No Gaza WPV1 cases confirmed (was cVDPV2), so that specific outbreak doesn't affect this market. # Calibration anchors - **Kalshi anchor**: 10.30% YES - **Base rate**: GPEI has missed every major deadline since 2000; zero-case year has not been achieved in WPV1 since ~2021 briefly in some regions but globally never post-2014. - **Trajectory**: Declining 2025–2026 cases are modestly encouraging but environmental data shows transmission well above zero; achieving true interruption within 3 years from ongoing endemic transmission is historically rare.

1. Both forecasters treat the 2026 mid-year figure of "3 cases" as straightforwardly encouraging, but the brief explicitly warns that "seasonality means more cases typically appear mid-year," making the partial-year count unreliable as a trend signal. Neither forecaster flags this caveat adequately. 2. The environmental surveillance signal is underweighted relative to clinical case counts. The brief notes 443 WPV1-positive environmental samples in 2025 (versus 741 in 2024), including a Kandahar-linked detection in Germany in October 2025—indicating that silent transmission remains geographically broad even as paralytic cases fall, which makes a true zero-case year substantially harder than the clinical decline alone suggests. 3. Neither forecaster explicitly quantifies the "deadline missed" base rate as a calibration anchor. GPEI has missed every major deadline since 2000, and the current interruption target (end-2025) was already missed; a pattern of serial ~2-year slippages implies the probability of achieving interruption within the remaining ~3.5 years is lower than a simple trend extrapolation would suggest. 4. Both forecasters essentially anchor to Kalshi (10.3%) and adjust minimally, but neither independently derives a probability from first principles (e.g., conditional probability of interruption by end-2028 given current reservoir persistence). This makes the forecasts tautologically dependent on the market price rather than independently validating it. 5. The scenario where cases drop to near-zero but a single sporadic case still occurs in 2028 or 2029 (preventing Yes resolution) is not discussed by either forecaster, even though the brief's framing—requiring a full calendar year of zero cases—means even one late-season case in any year blocks resolution, making "near elimination" insufficient. 6. Forecast 2 gives 12% Yes versus Forecast 1's 10%, a small but non-trivial divergence, yet neither explains what specific evidence drives that gap; the difference appears to reflect arbitrary rounding rather than a substantive disagreement about any sub-question identified in the brief.

9% (50% confidence)

Yes: 9% No: 91%

Anchoring near Kalshi (10.3%) but adjusting slightly downward given the critique's valid points: mid-2026 partial-year counts are seasonally unreliable, environmental surveillance shows broad silent transmission, GPEI's serial deadline slippage pattern, and the strict requirement that even one sporadic case blocks Yes resolution. The declining trend is real but insufficient against entrenched structural barriers in Pakistan/Afghanistan.

Total pipeline time: 124.6s